 Hey guys, how you doing? This is your boy Rich from Rich TV Live and you too can join the club at richpicksdaily.com where you can learn how to win and trade. Hey guys, how you doing? This is your boy Rich from Rich TV Live, richtv.io, richpicksdaily.com, richtvlive.com and we got another potential banger, winner, rocket to put in your pocket, Saibon CYBN on the New York Stock Exchange, also in Canada under the same symbol, CYBN. And I absolutely love this pick because when you look at the chart, I think it's right near a 52 week low. It's got money in the bank. And I just believe that psychedelics have an opportunity to be really special. And this is a company that wants to revolutionize healthcare. They want to revolutionize mental healthcare. They're working on effective strategies for substance abuse, mental illness, anxiety. It's true. And I believe it's absolutely game changing. I know psychedelics have been a tough sector. There's been ups, there's been downs because it's a brand new sector. But I think this is a company that has what it takes to go a very long way. I believe they're undervalued, under-appreciated, under-exposed. I believe the price is right right now. I'm going to show you guys why, exclusively here with your boy Rich, from Rich to be live, make sure you subscribe. Now let's take a look at Saibon turning psychedelics into therapeutics. It's true, exclusively here with your boy Rich, from Rich to be live. Let's take a look. All right, so this is Saibon, CYBN, on the New York Stock Exchange and CYBN on the Neo Exchange, psychedelics to therapeutics trademarked as of March, 2022. This is their most updated investor deck, psychedelics to therapeutics, which is also trademarked at Saibon. We are on a mission to engineer transformative psychedelic therapeutics to improve patients' mental health and clinical outcomes. We are a leading biopharmaceutical company focused on four core areas of our ecosystem by actively pursuing novel drug discovery with optimized properties, robust IP portfolios for each molecule, proprietary psychological support program, MBARC trademarked for patients and clinical facilitators, treatments for mental health conditions with large unmet needs. You can see here a strong leadership team. Our team has a deep rooted psychedelic pharmaceutical regulatory and academic research expertise with more than 400 years of combined experience in drug development. You can see the big names in corporate, R&D, clinical, academic and advisors. Successfully helped develop widely used drugs such as Allegra, Sabrel, Anzamet, Venika, Cyprexa, Sambalta, Nupro and Vimpat. Overseeing 60 plus IND programs with the FDA, Food and Drug Administration, worked on the development for the first FDA approved psychedelic compound, which is covered by healthcare insurance. You can see the Saibin history and key milestones. So there's some big, big milestones, including former Pfizer Asia president, Teresa Firestone, elected to board of directors and launched the MBARC trading psychedelic facilitator training program in October, 2021. Just recently in November, 2021, investigational, psilocybin, analog, CYB003 shows positive preclinical data, including significant advantages over oral psilocybin. And recently as early as February, 2022, the Chopra Foundation, huge, huge, huge name, partnership with Saibin, as well as other big news as you can see here, that has been happening and huge milestones that are beginning reached. August, 2021, they uplisted to the New York Stock Exchange in America, began trading under the symbol CYBN. So, and in November, 2020, began trading on the Neo Exchange in Canada under the symbol CYBN. It was founded in December, 2019 by three Toronto-based co-founders. So those are some of the key things and highlights that have been happening here with CYBN, corporate and financial highlights, as you can see here, over 120 million raised and well-funded to progress clinical trials, M&A mergers and acquisitions, NIP strategies, strategic shareholders, including long-term US institutional funds. So nice to see that there's some big institutional funds in the deal, cash and equivalents of 63.6 million as of December 31st, 2021. So lots of money in the bank, almost $63.6 million covered by nine research firms and inclusion in three psychedelic ETFs. So this is a quality psychedelic company. If you're looking for one, you need to put Saibin on your radar and on your watch list, you can see strong intellectual properties and grown from five to 50 employees across four countries, Canada, the United States, UK and Ireland developed 50 novel compounds with 10 patent filings across three patent families, completed more than 140 pre-clinical studies supporting R&D research and development, advancement of proprietary psychedelic-based molecules. So a lot of success for this company and it's been a tough sector. You can see here, I'm gonna show you the price of the stock and how it's traded. So initially it started kind of where it is right now and it just ran from like a dollar all the way to, let's just say in the last year. If we go to all actually, we just click on all here. Let's see if we can see this here. So we go to all and I always like to mark the high high, which is $4 in Canada and the low low, which was around, let's say 63 cents. So the lowest this has ever traded is 63 cents. The highest it's traded is $4 and they have 63.6 million in the bank and the stock is trading at 96 cents in Canada. To me, it looks like it's near a bottom. You can clearly see that it's gone up and it's come right back down. So the trend has gone up and then down. So we've seen that with lots of stocks, even some of the biggest stocks and a lot of smaller stocks have done this as well, where they've done this huge trend up and when the markets were super hot and you can see it hit its high in July of 2021 and then since then has come back down and it's kind of at the bottom. So could it go lower? Absolutely, anything is possible, but I really believe that there's some upside here as an investor for us to look at here for a company with, like I said, 63 million of the bank and to be a very well-rounded psychedelic play with already lots of experience and a strong team behind it, money in the bank and already doing a lot of work. So I just feel like it's really low and these are the types of entries we like to get into anything that we're buying because then if you get in and it goes back up and let's just say it goes back to this $4 remark where it did before, now you have a chance to make 300% on the stock. So these are the types of stocks that we like to invest in. These are the type of stocks we like to look at. These are the stocks that we're interested in, CYBN in Canada and on the New York Stock Exchange at only 77 cents. And once again, you can see here, it trended up, went all the way up and then came all the way down. So what's gonna be the next move? Typically it goes up again. So if the company is a growing company and they have strong results and strong revenue growth and a strong balance sheet and a tight share structure, we can see them go up, come down and then a lot of times they go right back up again. If the company's struggling and they're having problems and the company's losing money and not moving forward and growing as a public company and not profitable and showing quarter after quarter revenue growth, then you could see a stock go lower. So we've seen this go up, we've seen it go down. The question is, will it go up again? And if it does, it has a huge gap to fill which means there's money to be made right here. And that's what we like to look for. Now we can go and see Saibin's website right here, Changing Minds, this is their website Saibin.com. So I just wanted to show you their website. What we do, we earn a mission to revolutionize mental health care. Saibin is a leading, ethical, biopharmaceutical company working on a network of world-class partners and internationally recognized scientists on a mission to create safe and effective therapeutics for patients to address a multiple multitude of mental health issues. The company is focused on progressing psychedelics to therapeutics by engineering proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for mental health disorders. There's also a video you can watch. We're not gonna watch it right now because you can always go to Saibin.com and watch the video. And if you'd like to receive news and updates, just put in your email address and submit. Also, this is their LinkedIn page. I am also following them on LinkedIn and you can learn more about them on LinkedIn. And I like to follow companies everywhere so I can really get to know, you know what they're doing on social media, get a chance to understand like here, for example, on Instagram, they have 13,000 followers, 51 posts. So you can come here, you can see the posts, get a feel for the community, get a feel for the work they're doing. I think it's important to do that as an investor. You need to know what you're investing into. And the more you know about a company you're investing into, I feel like the better investment decisions you can make. This is their Twitter page, psychedelics to therapeutics we're on a mission to revolutionize mental healthcare. CYBN, you can see 6,911 followers on Twitter. So they have a growing community and really they're just getting started in early stage pharmaceutical, early stage psychedelic pharmaceutical company that I believe is extremely at these prices. This is their Facebook. I'm also following them on Facebook. You can see here 11,872 people like this. So 12,000 people follow CYBN on Facebook. So good to see a nice community there on Facebook. And once again, their website and once again, the stock being down, right? This is where we like to position ourselves. We love to position ourselves in growing companies and value stocks at 52 week lows, at bottoms. This is the rich system. This is a rich method. Buy the dips, sell the rips, invest in the best. The best is blessed. And this is a company that has a chance to be one of the best psychedelic pharmaceutical companies out there. And this is why I believe, and I've talked about this even though this is a sector that has been really heavily oversold in my opinion. I believe that this is breakthrough technology. This is breakthrough therapy that has the chance to change the world. Academic studies demonstrate efficacy of psychedelic treatment. And I really believe there was a lot of excitement initially and you saw a lot of people got into the sector and we see a huge move. Like before they dropped, they all made big moves, right? Big moves up. So there was money to be made. And then everything got taken off the table. And I just feel like a lot of them are setting up for another big move. Love to know what you guys think. It's your boy, Rich from Rich to be live. Bring you Cybin on the New York Stock Exchange, Cybin and in Canada. Cybin, put on your radar, put on your watch list. I believe it's very close to a bottom and I believe that the upside could be a multiple for early investors. Love to know what you guys think. If you like the video, comment on the video, smash the like button, share the video so it gets as many eyeballs as humanly possible. Let me know what you guys think. It's your boy, Rich from Rich to be live. And I'm out.